{
  "ticker": "KRYS",
  "company_name": "Krystal Biotech, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT04917874",
      "title": "A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa",
      "start_date": "2021-05-25",
      "completion_date": "2023-07-31",
      "enrollment": 0,
      "sponsor": "Krystal Biotech, Inc."
    },
    {
      "nct_id": "NCT06228326",
      "title": "A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs",
      "status": "RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Lung Cancer, Non-small Cell, Lung Cancer Metastatic, Solid Tumor, Adult, Advanced Cancer, Lung Cancer (NSCLC)",
      "start_date": "2024-04-17",
      "completion_date": "2028-07",
      "enrollment": 0,
      "sponsor": "Krystal Biotech, Inc."
    },
    {
      "nct_id": "NCT05095246",
      "title": "A Study of Inhaled KB407 for the Treatment of Cystic Fibrosis",
      "status": "WITHDRAWN",
      "phase": "PHASE1",
      "condition": "Cystic Fibrosis",
      "start_date": "2022-03-08",
      "completion_date": "2024-10-30",
      "enrollment": 0,
      "sponsor": "Krystal Biotech, Inc."
    },
    {
      "nct_id": "NCT04214002",
      "title": "The Natural History of Wounds in Patients With Dystrophic Epidermolysis Bullosa (DEB)",
      "status": "WITHDRAWN",
      "phase": "",
      "condition": "Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa",
      "start_date": "2020-01",
      "completion_date": "2020-02-24",
      "enrollment": 0,
      "sponsor": "Krystal Biotech, Inc."
    },
    {
      "nct_id": "NCT05735158",
      "title": "Topical KB105 for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)",
      "status": "UNKNOWN",
      "phase": "PHASE2",
      "condition": "Autosomal Recessive Ichthyosis",
      "start_date": "2023-03",
      "completion_date": "2024-04",
      "enrollment": 0,
      "sponsor": "Krystal Biotech, Inc."
    },
    {
      "nct_id": "NCT07016750",
      "title": "A Study Assessing KB803 Compared to Matching Placebo for the Treatment and Prevention of Corneal Abrasions in Dystrophic Epidermolysis Bullosa",
      "status": "RECRUITING",
      "phase": "PHASE3",
      "condition": "Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa",
      "start_date": "2025-06-20",
      "completion_date": "2026-03",
      "enrollment": 0,
      "sponsor": "Krystal Biotech, Inc."
    },
    {
      "nct_id": "NCT04917887",
      "title": "Long-Term Follow-up Protocol",
      "status": "RECRUITING",
      "phase": "",
      "condition": "Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa",
      "start_date": "2021-05-25",
      "completion_date": "2028-05-25",
      "enrollment": 0,
      "sponsor": "Krystal Biotech, Inc."
    },
    {
      "nct_id": "NCT03536143",
      "title": "A Phase I/II Study of KB103, a Topical HSV1-COL7, on DEB Patients",
      "status": "COMPLETED",
      "phase": "PHASE1, PHASE2",
      "condition": "Dystrophic Epidermolysis Bullosa",
      "start_date": "2018-05-06",
      "completion_date": "2019-11-01",
      "enrollment": 0,
      "sponsor": "Krystal Biotech, Inc."
    },
    {
      "nct_id": "NCT05504837",
      "title": "A Study Assessing KB407 for the Treatment of Cystic Fibrosis",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Cystic Fibrosis",
      "start_date": "2023-06-30",
      "completion_date": "2026-01",
      "enrollment": 0,
      "sponsor": "Krystal Biotech, Inc."
    },
    {
      "nct_id": "NCT06724900",
      "title": "A Study Assessing KB304 for the Treatment of Wrinkles in Women",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Wrinkles in Decolletage, Pigmentation, D\u00e9collet\u00e9 Wrinkles",
      "start_date": "2024-11-20",
      "completion_date": "2025-08",
      "enrollment": 0,
      "sponsor": "Krystal Biotech, Inc."
    }
  ],
  "summary": {
    "total_trials": 17,
    "by_phase": {
      "PHASE3": 3,
      "PHASE1, PHASE2": 6,
      "PHASE1": 4,
      "": 3,
      "PHASE2": 1
    },
    "by_status": {
      "COMPLETED": 3,
      "RECRUITING": 8,
      "WITHDRAWN": 2,
      "UNKNOWN": 2,
      "ACTIVE_NOT_RECRUITING": 2
    },
    "active_trials": 10,
    "completed_trials": 3,
    "conditions": [
      "Alpha 1-Antitrypsin Deficiency",
      "Autosomal Recessive Ichthyosis",
      "Cancer, Melanoma Stage III, Melanoma Stage IV, Cutaneous Melanoma",
      "Cystic Fibrosis",
      "Dystrophic Epidermolysis Bullosa",
      "Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa",
      "Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa",
      "Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa",
      "Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa Dystrophica, Recessive, Epidermolysis Bullosa Dystrophica Dominans",
      "Lung Cancer, Non-small Cell, Lung Cancer Metastatic, Solid Tumor, Adult, Advanced Cancer, Lung Cancer (NSCLC)",
      "Neurotrophic Keratitis",
      "Skin Roughness, Wrinkle, Fine Lines, Skin Thickness",
      "TGM-1 Related Autosomal Recessive Congenital Ichthyosis",
      "Wrinkles in Decolletage, Pigmentation, D\u00e9collet\u00e9 Wrinkles"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:19:29.975282",
    "search_query": "Krystal Biotech, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Krystal+Biotech,+Inc."
  }
}